Vertex Pharmaceuticals Incorporated
NASDAQ:VRTXBiotechnology
-$6.43 today
- Market cap
- $136.01B
- Beta
- 0.31
- P/E (TTM)
- 26.5
- EPS (TTM)
- $17.07
Volume 1.29M
Average 1.26M
VRTX Sales of Investments
Cash received from selling or redeeming investments.
Vertex Pharmaceuticals IncorporatedNASDAQ: VRTX
Sales of Investments · Q2 FY2026 · quarter ended Jun 2026
Sales of investments growth accelerates
Q2 FY2026 sales of investments of $2.42B rose 31.9% year over year, ahead of the +16.9% change in trailing-twelve-month sales of investments. Sequentially, it rose 9.8% from the prior quarter. Over 3 fiscal years it compounded at +85.9% a year.
Context
- Sales of investments amounted to 49.0% of revenue in FY2025, up 8.5 pp from a year earlier.
- Sales of investments increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +31.9% holds above the trailing-twelve-month pace of +16.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 5.91B USD
- Year-over-year change
- +32.4%
- 4-year CAGR
- +85.5%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.91B | +32.4% |
| FY2024 | 2024-12-31 | 4.47B | +378.0% |
| FY2023 | 2023-12-31 | 934.2M | +1.5% |
| FY2022 | 2022-12-31 | 920M | +84.3% |
| FY2021 | 2021-12-31 | 499.3M | — |
Sales of Investments vs competitors
How VRTX compares with its peers on the latest reported figures
- VRTX's LTM Jun 2026 sales of investments of $7.07B is the 2nd largest of the 11 companies compared; the peer median is $1.05B.
- Its year-over-year change of +16.9% is the 5th highest of 11, against a peer median of +4.1%.
- Sales of investments amounts to 56.0% of revenue for VRTX, versus a peer median of 103.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $767.32B | +170746.3% | -18.3% | 74.7% | |
| LTM Jun 2026 | $7.07B | +16.9% | +85.9% | 56.0% | |
| LTM Sep 2026 | $1.82B | +4.9% | +19.7% | 189.3% | |
| LTM Jun 2026 | $1.43B | -16.9% | -6.9% | 29.8% | |
| LTM Jun 2026 | $1.34B | +87.1% | +18.2% | 132.6% | |
| LTM Sep 2026 | $1.12B | +3.3% | -5.4% | 4449.2% | |
| LTM Mar 2026 | $981.03M | +2.6% | +17.3% | 1484.3% | |
| LTM Jun 2026 | $818.71M | +17.6% | -11.0% | 524.7% | |
| LTM Mar 2026 | $395.01M | -5.6% | -6.6% | 59.0% | |
| LTM Mar 2026 | $294M | -81.2% | -20.2% | 13.5% | |
| LTM Jun 2026 | $50.6M | +26.5% | -72.6% | 7.1% | |
| Peer median (excluding VRTX) | $1.05B | +4.1% | -6.7% | 103.6% | |
Competitors are the stored peer set for VRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 2.34B | 3.32B | 3.62B | (535.6M) | 3.95B |
| Depreciation & Amortization | 125.6M | 148.3M | 181.3M | 207.2M | 209.8M |
| Deferred Income Tax | (154.6M) | (275.9M) | (536.5M) | (348.8M) | (510.8M) |
| Stock-Based Compensation | 441.4M | 491.3M | 581.2M | 698.5M | 685.9M |
| Change in Working Capital | (105.2M) | 340.8M | (265.7M) | (514.8M) | (1.2B) |
| Accounts Receivables | (274.7M) | (358.6M) | (84.1M) | (99.3M) | (347.3M) |
| Inventory | (92.8M) | (136.4M) | (322.9M) | (517.3M) | (524.2M) |
| Accounts Payables | 31.9M | 120.8M | 48.7M | 49.5M | 36.8M |
| Other Working Capital | 230.4M | 715M | 92.6M | 52.3M | (364.4M) |
| Other Non-Cash Items | (5.8M) | 103.4M | (42.6M) | 900K | 492.4M |
| Operating Cash Flow | 2.64B | 4.13B | 3.54B | (492.6M) | 3.63B |
| Capital Expenditures | (235M) | (204.7M) | (258.4M) | (297.7M) | (437.6M) |
| Acquisitions (Net) | 77M | (295.9M) | 0 | 0 | 0 |
| Purchases of Investments | (605.2M) | (692.7M) | (3.79B) | (7.7B) | (6.4B) |
| Sales of Investments | 499.3M | 920M | 934.2M | 4.47B | 5.91B |
| Other Investing Activities | (77M) | (47.8M) | (89M) | (241.7M) | (24.7M) |
| Investing Cash Flow | (340.9M) | (321.1M) | (3.14B) | (3.77B) | (945.4M) |
| Debt Repayment | (18.7M) | (85.5M) | (44.9M) | (33.6M) | (5.4M) |
| Common Stock Issued | 102M | 186.3M | 134.6M | 114.6M | 127.7M |
| Common Stock Repurchased | (1.43B) | (172M) | (427.6M) | (1.18B) | (2.02B) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (130.2M) | 3.5M | (224.3M) | (398.8M) | (366.2M) |
| Financing Cash Flow | (1.48B) | (67.7M) | (562.2M) | (1.49B) | (2.26B) |
| Effect of Forex Changes | (13.4M) | (29.2M) | 26.9M | (42.6M) | 90.9M |
| Net Change in Cash | 811.2M | 3.71B | (139.7M) | (5.8B) | 515.6M |
| Free Cash Flow | 2.41B | 3.93B | 3.28B | (790.3M) | 3.19B |
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
Intrinsic Alpha fair value
Locked
Current Price
$536.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.